Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS

Drug Testing and Analysis

Volumn 6, Issue 10, 2014, Pages 1038-1048

  Wink, Carina S D ^a   Meyer, Golo M J ^a   Wissenbach, Dirk K ^a,c   Jacobsen Bauer, Andrea ^b   Meyer, Markus R ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Landeskriminalamt Baden Wurttemberg   (Germany)

^c HELMHOLTZ CENTRE FOR ENVIRONMENTAL RESEARCH UFZ   (Germany)

Author keywords

Designer drugs; GC MS; LC HR MS MS; Lefetamine derivatives; Metabolism

Indexed keywords

ALKYLATION; BIOMOLECULES; BODY FLUIDS; DRUG PRODUCTS; GAS CHROMATOGRAPHY; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHYSIOLOGY; RATS; SCREENING;

DESIGNER DRUGS; DETECTABILITY; GASCHROMATOGRAPHY-MASS SPECTROMETRY; LC-HR-MS/MS; LC-MS N; LEFETAMINE DERIVATIVE; N-DEALKYLATION; PHASE I; RAT URINE; SCREENING APPROACHES;

METABOLISM;

DESIGNER DRUG; HYDROXYL GROUP; LEFETAMINE; N ETHYL 1,2 DIPHENYLETHYLAMINE; N ISO PROPYL 1,2 DIPHENYLETHYLAMINE; UNCLASSIFIED DRUG; N-ETHYL-1,2-DIPHENYLETHYLAMINE; N-ISOPROPYL-1,2-DIPHENYLETHYLAMINE; PHENETHYLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DEALKYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; GLUCURONIDATION; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SULFATION; TANDEM MASS SPECTROMETRY; URINALYSIS; ANIMAL; GERMANY; METABOLISM; PROCEDURES; URINE; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GERMANY; MALE; PHENETHYLAMINES; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84916941127     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1621     Document Type: Article

References (28)

1. M.G. De Montis, P. Devoto, A. Bucarelli, A. Tagliamonte. Opioid activity of lefetamine. Pharmacol. Res. Commun. 1985, 17, 471.
2. L. Janiri, P. Mannelli, A.M. Persico, A. Serretti, E. Tempesta. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 1994, 36, 139.
3. P. Mannelli, L. Janiri, M.M. De, E. Tempesta. Lefetamine: new abuse of an old drug-clinical evaluation of opioid activity. Drug Alcohol Depend. 1989, 24, 95.
4. F. Westphal, T. Junge, A. Jacobsen-Bauer, P. Rösner. Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech 2010, 77, 46.
5. M.L. Tainter, F.P. Luduena, R.W. Lackey, E.N. Neuru. Actions of a series of diphenyl-ethylamines. J. Pharmacol. Exp. Ther. 1943, 77, 317.
6. M.L. Berger, A. Schweifer, P. Rebernik, F. Hammerschmidt. NMDA receptor affinities of 1, 2-diphenylethylamine and 1-(1, 2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg. Med. Chem. 2009, 17, 3456.
7. Bluelight. http://www.bluelight.org/vb/ [14 February 2014].
8. Forum Opiophile. http://forum.opiophile.org/forum.php [14 February 2014].
9. Drug-Forums. http://www.drugs-forum.com/index.php [14 February 2014].
10. H.H. Maurer, K. Pfleger, A.A. Weber. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. Wiley-VCH: Weinheim (Germany), 2011.
11. D.K. Wissenbach, M.R. Meyer, D. Remane, A.A. Philipp, A.A. Weber, H.H. Maurer. Drugs of abuse screening in urine as part of a metabolite-based LC-MS(n) screening concept. Anal. Bioanal. Chem. 2011, 400, 3481.
12. Bundesrepublik Deutschland. Tierschutzgesetz. http://www.gesetze-im-internet.de/bundesrecht/tierschg/gesamt.pdf, 2013.
13. J. Welter, M.R. Meyer, E. Wolf, W. Weinmann, P. Kavanagh, H.H. Maurer. 2-Methiopropamine, a thiophene analogue of methamphetamine: Studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal. Bioanal. Chem. 2013, 405, 3125.
14. M.R. Meyer, C. Vollmar, A.E. Schwaninger, H.H. Maurer. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J. Mass Spectrom. 2012, 47, 253.
15. D.K. Wissenbach, M.R. Meyer, D. Remane, A.A. Weber, H.H. Maurer. Development of the first metabolite-based LC-MSn urine drug screening procedure - exemplified for antidepressants. Anal. Bioanal. Chem. 2011, 400, 79.
16. National Institute of Standards and Technology. Automated Mass Spectral Deconvolution and Identification System (AMDIS). http://chemdata.nist.gov/mass-spc/amdis/, 2012.
17. M.R. Meyer, F.T. Peters, H.H. Maurer. Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin. Chem. 2010, 56, 575.
18. H.H. Maurer, K. Pfleger, A.A. Weber. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. Wiley-VCH: Weinheim (Germany), 2011.
19. H.H. Maurer, D.K. Wissenbach, A.A. Weber. Maurer/Wissenbach/Weber MWW LC-MSn Library of Drugs, Poisons, and their Metabolites. Wiley-VCH: Weinheim, 2014.
20. F.W. McLafferty, F. Turecek. Interpretation of Mass Spectra. University Science Books: Mill Valley, CA, 1993.
21. R.M. Smith, K.L. Busch. Understanding Mass Spectra - A Basic Approach. Wiley: New York (NY), 1999.
22. H.H. Maurer, J. Bickeboeller-Friedrich, T. Kraemer. Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine. J. Chromatogr. B. 2000, 739, 325.
23. M.R. Meyer, H.H. Maurer. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 2009, 22, 1205.
24. H.F. Grützmacher, S. Dohmeier-Fischer. Polycondensation of benzyl methyl ether by reaction with gaseous benzyl cations - a potpourri of mechanisms of organic ion/molecule reactions. Int. J. Mass Spectrom. 1998, 180, 207.
25. P.A. Weibel, M. Hesse. Substituenteneinfluss bei der massenspektrometrischen Fragmentierung: Untersuchungen an N-methyl-ß, ß'-diphenyl-diäthylaminen. 19. Mitteilung über das massenspektrometrische Verhalten von Stickstoffverbindungen. Helv. Chim. Acta. 1973, 56, 2460.
26. S. Bourcier, Y. Hoppilliard. Fragmentation mechanisms of protonated benzylamines. Electrospray ionisation-tandem mass spectrometry study and ab initio molecular orbital calculations. Eur. J. Mass Spectrom. (Chichester, Eng.) 2003, 9, 351.
27. V. Sharma, J.H. McNeill. To scale or not to scale: the principles of dose extrapolation. Br. J. Pharmacol. 2009, 157, 907.
28. D.K. Wissenbach, M.R. Meyer, A.A. Weber, D. Remane, A.H. Ewald, F.T. Peters, H.H. Maurer. Towards a universal LC-MS screening procedure - can an LIT LC-MSn screening approach and reference library be used on a quadrupole-LIT hybrid instrument? J. Mass Spectrom. 2012, 47, 66.